/
Our Company We are a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. We are focused on the development and commercialization of innovative product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI and rare diseases.
Margins and capital returns are both well above average: 33.26% operating margin, ROIC at 46.13%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue declined 15.7% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$362M
▼ -15.7% YoY
Net Income (TTM)
$102M
▲ +2629.2% YoY
Op. Margin
55.37%
▲ +6.8pp YoY
ROIC
115.70%
▲ +11.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$112M
▲ +22.8% YoY
Op. Cash Flow (TTM)
$112M
▲ +22.7% YoY
Net Debt
-$208M
Net Cash Position
Cash & Equiv.
$220M
5Y CAGR: -5.3%
5Y CAGR: -5.3%
Continue Research